Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in SSc-ILD
NCT03856853Phase 3Unknown
- Sponsor
- Gyre Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pirfenidone in systemic sclerosis-associated interstitial lung disease (SSc-ILD), sponsored by Gyre Pharmaceuticals. Status: unknown.
02
Drugs
pirfenidone
03
Conditions
systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Beyond the preview
Go deeper on NCT03856853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856853.